NCT03966651
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03966651
Title A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)
Acronym NEUROBLU 02
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut Claudius Regaud
Indications
Therapies
Age Groups: adult | child
Covered Countries FRA

Facility Status City State Zip Country Details
CHU Angers RECRUITING Angers France Details
CHU Besançon RECRUITING Besançon France Details
CHU Pellegrin RECRUITING Bordeaux France Details
CHU Dijon RECRUITING Dijon France Details
CHU de Grenoble RECRUITING Grenoble France Details
Centre Oscar Lambret RECRUITING Lille France Details
Centre Léon Bérard RECRUITING Lyon France Details
Hopital Arnaud de Villeneuve RECRUITING Montpellier France Details
CHU Nancy RECRUITING Nancy France Details
CHU Nantes RECRUITING Nantes France Details
CHU Reims RECRUITING Reims France Details
CHU Strasbourg RECRUITING Strasbourg France Details
CHU de Toulouse - Hôpital des enfants RECRUITING Toulouse France Details
IUCT-O RECRUITING Toulouse France Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field